Benzodiazepine Receptor Antagonist Pregnancy: Caution — limited data; use only if clearly indicated for reversal of inadvertent benzodiazepine overdose in pregnancy

Flumazenil

Brand names: Anexate

Adult dose

Dose: 200 mcg IV over 15 seconds; repeat 100 mcg every 60 seconds to desired effect; total dose usually 300–600 mcg; rarely >1 mg required

Route: Intravenous

Frequency: Titrated dosing; repeat doses every 60 seconds as needed

Max: 3 mg total in one episode

Reversal of benzodiazepine sedation — procedural, diagnostic; short duration of action (30-60 min) — re-sedation common as flumazenil clears before benzodiazepine; monitor closely for 1-2 hours after last dose

Paediatric dose

Dose: 10 mcg/kg IV over 15 seconds; repeat 10 mcg/kg every 60 seconds mcg/kg

Route: Intravenous

Frequency: Titrated to effect

Max: 40 mcg/kg or 2 mg total (whichever is less)

Paediatric reversal of procedural sedation; MHRA licensed ≥1 year; BNFc

Dose adjustments

Renal

No dose adjustment required — hepatically metabolised

Hepatic

Use with caution in severe hepatic impairment — prolonged action possible

Paediatric weight-based calculator

Patient weight (kg)

Paediatric reversal of procedural sedation; MHRA licensed ≥1 year; BNFc

Clinical pearls

Re-sedation is the dominant clinical concern: flumazenil has a half-life of 40-80 minutes vs diazepam (20-70h), lorazepam (10-20h), midazolam (2-6h) — patient will re-sedate as flumazenil clears; never discharge after flumazenil without adequate observation period (≥1h for short-acting BZD, longer for long-acting)
Chronic BZD dependency contraindication: flumazenil in a BZD-dependent patient precipitates acute benzodiazepine withdrawal — potentially fatal seizures; NEVER give flumazenil without confirming absence of chronic benzodiazepine use; unreliable history requires caution
NOT a diagnostic test: giving flumazenil to distinguish BZD sedation from other causes of unconsciousness is unreliable — a patient who doesn't respond may have non-BZD CNS depression; a patient who partially responds may have mixed ingestion; response is not diagnostic
Mixed TCA-BZD overdose: benzodiazepines may be protective against TCA-induced seizures and arrhythmias; reversing BZD with flumazenil can unmask TCA toxicity — avoid in context of suspected tricyclic co-ingestion (wide QRS, QTc prolongation)
Procedural sedation reversal: routine reversal with flumazenil at end of benzodiazepine-based sedation (e.g. endoscopy) is acceptable — patient must still be observed for re-sedation; discharge criteria based on clinical assessment, not flumazenil administration

Contraindications

Chronic benzodiazepine therapy — precipitates acute withdrawal (seizures)
Seizure threshold lowering situations (head injury, status epilepticus on benzodiazepines)
Mixed benzodiazepine-tricyclic overdose (unmasking TCA toxicity by reversing sedation can worsen arrhythmias)

Side effects

Acute benzodiazepine withdrawal (agitation, anxiety, seizures — in dependent patients)
Nausea
Dizziness
Re-sedation (flumazenil wears off before benzodiazepine)
Seizures (in epileptics receiving chronic BZD)

Interactions

Benzodiazepines — competitively antagonised; dose-dependent reversal
Tricyclic antidepressants — unmasking TCA toxicity after reversing BZD sedation is dangerous in mixed overdose

Monitoring

Level of consciousness (every 15 min post-dose)
Respiratory rate and SpO2
ECG (in overdose context)
Re-sedation surveillance (1-2 hours)
Seizure activity (in withdrawal risk patients)

Reference: BNFc; BNF 90; BNFc; MHRA SPC Anexate; TOXBASE NPIS; Hojer et al. J Toxicol Clin Toxicol 1996 (flumazenil in BZD overdose). Verify against your local formulary and the latest BNF before prescribing.

Curated clinical cross-links plus same-class fallbacks.

Calculators